g. West Africa in 2010 and East Africa in 2011). selleck chemical Frequently, WFH work within a country begins with the identification of a core group of medical professionals interested in the provision of care to patients with bleeding

disorders. The WFH-funded and facilitated HTC twinning programme pairs emerging HTCs with established ones to help increase the levels of diagnosis and medical attention for people with haemophilia [29]. Encouraging the establishment of medical twinning partnerships allows countries to advance on an individual level as well. At present, WFH has established or plans to establish medical twinning partnerships in all the WFH member countries within the region. To date 11 twinnings have been established†. Twinning has proven to be a highly successful way to introduce care and build the core of medical expertise within a country. Using an example from another region, twinning programmes within China led to the development of a national treatment centre network and have served as the catalyst for the further development of care nationally [30]. The WFH has established that one international unit (IU) of FVIII CFC per capita should be the target minimum for countries wishing to achieve optimal survival for the haemophilia population. Overall, among the WFH NMOs reporting usage

of FVIII within Africa, the IU per capita ranges from 0.00036 in Nigeria to 0.715 in South Africa with an overall African Z-VAD-FMK price average of 0.14. For comparison, globally the FVIII IU per capita for countries with a gross domestic product (GDP) < $US 2000 is 0.024. For countries with a GDP $US 2000 to 10 000 the FVIII IU per capita is 1.03 [1,32,33]. Health authorities in these countries typically provide clotting factor concentrates (CFCs) to people with haemophilia, although at a low level, usually less than one IU of FVIII CFC per capita 上海皓元医药股份有限公司 and utilize appropriate laboratory diagnosis [1]. The WFH has established that one IU of

FVIII per capita should be the target minimum for countries wishing to achieve optimal survival for the haemophilia population [31]. As most patients within the Southern African region have some access to CFCs, the morbidity and mortality manifest differently than in other regions. WFH advocacy work within this region has focused on increasing the quantity of CFCs provided and expanding care to include other bleeding disorders as well as targeted support for the introduction of treatment for patients with inhibitors. From a clinical perspective, WFH work in this region focuses on the development and adoption of treatment guidelines to harmonize management for patients with bleeding disorders across each country.